| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2019: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2018: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Outline of Final Research Achievements |
To establish a strategy of drug development for ABC transporter-related diseases, we analyzed molecular mechanism underlying degradation mechanism of cell surface-resident ABCA1, an ABC transporter that has an inhibitory effect on atherosclerosis.
This is based on our basic and clinical evidence obtained from studies of other ABC transporters. We have performed library screening, interactome analysis, and subsequent verification experiments using cultured cells and genetically modified mice and
identified multiple molecules that promote the degradation of cell surface-resident ABCA1.
|
